Overview
Ipsen SA reported second‑quarter 2026 product sales of €1,115 million, exceeding its internal consensus of €1,048 million by €67 million (6% above) and representing a 24.5% increase at constant exchange rates (CER) from €901 million a year earlier. The growth was driven by Somatuline, whose CER sales rose 29.7% to €358 million, beating the €330 million consensus by €27 million (8% above) amid limited generic competition.
First‑Half Performance
First‑half total (product) sales reached €2,190.2 million, up 20.4% year‑on‑year on a reported basis and 23.5% at CER, surpassing the consensus of €2,123 million by €67 million. Core operating income increased 28.8% to €844.9 million, delivering a core operating margin of 38.6%, which beat the consensus margin of 36.0% by 261 basis points. Core consolidated net profit rose 19.6% to €607.7 million, while core earnings per share grew 20.7% to €7.33 from €6.07. IFRS‑based consolidated net profit was €402.6 million, a 20.0% increase from €335.5 million a year earlier.
Guidance Update
The company lifted its full‑year 2026 guidance, now targeting total sales growth of greater than 20.0% at CER (previously >13.0%) and a core operating margin of greater than 37.0% of sales (previously >35.0%). An adverse currency effect of approximately 1% on total sales is anticipated based on average June 2026 exchange rates. The revised outlook assumes accelerated growth of the portfolio excluding Somatuline and continued Somatuline expansion despite the potential entry of generic lanreotide.
Clinical Development
Ipsen announced positive Phase III topline results for Dysport in both episodic and chronic migraine and for Iqirvo in primary biliary cholangitis. Conversely, the Phase III trial of Bylvay in biliary atresia did not meet its primary endpoint of improved native liver survival.
Strategic Transactions
The company disclosed the acquisition of Memo Therapeutics AG and entered into an agreement to acquire Kartos Therapeutics, with the Kartos transaction expected to close by the end of the third quarter of 2026.
Cash Position
Closing net cash stood at €1,004.9 million as of 30 June 2026, up from €487.6 million a year earlier. Free cash flow increased 34.9% to €651.7 million from €483.2 million.
Management Commentary
Chief Executive Officer David Loew stated that the first‑half performance demonstrates the strength of Ipsen’s strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate.
Analyst Perspective
Barclays interpreted the raised guidance as implying 2026 revenue of €4,366 million, 4% above the company’s internal consensus of €4,195 million, and core operating income of €1,615 million, 8% above the consensus of €1,498 million. Barclays set a target price of €170, applying a forward P/E multiple of about 12.5× projected 2027 earnings, representing roughly a 10% discount to the mid‑cap/specialty sector to reflect what it described as heightened loss‑of‑exclusivity risk and weaker mid‑term EPS growth outlook versus peers.
Market Reaction
Despite the upbeat results and guidance, Ipsen’s shares slipped on the day of the announcement.